Grant: Alliance Grants
University of Alberta
$108,000.00
Improvement of glycosyltransferases for in vitro glycan remodeling of plant derived therapeutic proteins.
EF 2021-22
Résumé
Plants represent an excellent cost-effective alternative to mammalian cell culture for production of protein based drugs known as biologics. These drugs are proteins derived from normal human biology, where they protect us from various natural and man-made toxins, infectious disease, and immune system malfunctions like cancer. These are produced as recombinant proteins and are very expensive to manufacture in tissue culture. Normal human therapeutic proteins are decorated with molecules called glycans making them "glycoproteins", and these glycans are essential for stability and longevity in the body. The biochemical machinery for making glycoproteins in plants and animals is almost identical, resulting in plants being able to make some important human proteins, like antibodies, and proteins which protect from toxins like nerve gas. Plants however don't naturally make human style glycan decorations on plants, and plant glycans can cause an allergic reaction. Recent advances in plant engineering now allows researchers to produce proteins without the plant specific decorations which make the proteins a target of the human immune system. However, the production of the authentic human glycan decorations is still difficult to control in both mammalian- and plant-based expression systems. PlantForm, and the Wakarchuk lab are collaborating to use enzymes in the laboratory to finish the glycan decorations exactly as those found on the normal human protein with the goal of commercial-scale glycan modification of target proteins. To this end, the enzymes required to change the glycans are being engineered for improved production, activity and stability through our unique bacterial expression systems. We are developing immobilized enzymes to produce various terminal glycan decorations such that the proteins don't require extensive re-purification after the reactions. We are also engineering production of these enzymes in a bacterium which doesn't produce a toxic contaminant - endotoxin - which requires significant effort to remove from these high value proteins.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
550399-2020
Name nom
Wakarchuk, Warren
Department département
Biological Sciences
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2021
Competition year année de concours
2020
Award amount
108000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
5404
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Enzymes
Research subject fr
Enzymes
Installment
inst:2
Partie
1
Nb partie
2
Application title
Improvement of glycosyltransferases for in vitro glycan remodeling of plant derived therapeutic proteins.
Keyword
NSERC
Application summary
Plants represent an excellent cost-effective alternative to mammalian cell culture for production of protein based drugs known as biologics. These drugs are proteins derived from normal human biology, where they protect us from various natural and man-made toxins, infectious disease, and immune system malfunctions like cancer. These are produced as recombinant proteins and are very expensive to manufacture in tissue culture. Normal human therapeutic proteins are decorated with molecules called glycans making them "glycoproteins", and these glycans are essential for stability and longevity in the body. The biochemical machinery for making glycoproteins in plants and animals is almost identical, resulting in plants being able to make some important human proteins, like antibodies, and proteins which protect from toxins like nerve gas. Plants however don't naturally make human style glycan decorations on plants, and plant glycans can cause an allergic reaction. Recent advances in plant engineering now allows researchers to produce proteins without the plant specific decorations which make the proteins a target of the human immune system. However, the production of the authentic human glycan decorations is still difficult to control in both mammalian- and plant-based expression systems. PlantForm, and the Wakarchuk lab are collaborating to use enzymes in the laboratory to finish the glycan decorations exactly as those found on the normal human protein with the goal of commercial-scale glycan modification of target proteins. To this end, the enzymes required to change the glycans are being engineered for improved production, activity and stability through our unique bacterial expression systems. We are developing immobilized enzymes to produce various terminal glycan decorations such that the proteins don't require extensive re-purification after the reactions. We are also engineering production of these enzymes in a bacterium which doesn't produce a toxic contaminant - endotoxin - which requires significant effort to remove from these high value proteins.